Plaque stabilization by LDL-apheresis?;Plaquestabilisierung durch LDL-apherese?

Herz

Volumn 24, Issue 1, 1999, Pages 57-61

  Schuff Werner, Peter ^a   Schettler, Volker ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b NONE

Author keywords

Coagulation factors; Fibrinogen; LDL apheresis; OxLDL; Plaque stabilisation; Unstable plaques; Viscosity

Indexed keywords

FIBRINOGEN; LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; APHERESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VISCOSITY; EARLY DIAGNOSIS; HEART REINFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; REVIEW; SHEAR STRESS; VASOMOTOR REFLEX;

EID: 0033049873     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03043819     Document Type: Review

References (20)

1. Bischoff H, Angerbauer R, Bender J, et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997;135:119-30.
2. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323: 1289-98.
3. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;5:1276-82.
4. Deckert V, Brunet A, Lantoine F, et al. Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1054-60.
5. DeGennes JL, Touraine R, Maunand B, et al. Formes homozygotes cutanes-tendineuses de xanthomatose hypercholesterolemique dans une observation famiale exemplaire. Essai de plasmapherese à titre de traitement héroique. Bull Mem Soc Hop Paris 1967;118:1377-402.
6. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med 1993; 118:956-63.
7. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
8. Huggins GS, Pasternak RC, Alpert NM, et al. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998;98:1291-6.
9. Kroon AA, Aengevaeren WRM, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Circulation 1996;93:1826-35.
10. Lane DM, McConathy WJ, Laughlin LO, et al. Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy. Atherosclerosis 1995;114:203-11.
11. Mellwig KP, Baller D, Gleichmann U, et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998;139:173-8.
12. Olbricht CJ. Extrakorporale Elimination von LDL-Cholesterin durch Apherese. Dtsch Med Wochenschr 1991;116:625-30.
13. Scandinavian Simvastatin Survival Study Group. Radomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group (4S). Lancet 1994;334:1383-9.
14. Schuff-Werner P, Claus G, Armstrong VW, et al. Enhanced pro-coagulatory activity (PCA) of human monocytes/macrophages after in vitro stimulation with chemically modified LDL. Atherosclerosis 1989;78:109-12.
15. Schuff-Werner P, Schütz E, Reitemeyer F, et al. Heparin-induced extracorporal LDL precipitation (HELP): Rheological, hemostaseological and immunological effects. In: Gotto AM Jr, Mancini M, Richter WO, et al., eds. Treatment of severe hypercholesterolemia in the prevention of coronary heart disease. Proc 2nd Int Symposium, Munich 1989. Basel: Karger, 1990:196-204.
16. Schuff-Werner P, Gohlke H, Bartman U, et al. The Help-Study Group. The HELP-LDL-apheresis multicentre study, an angio-graphically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
17. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
18. Tamai O, Matusuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
19. Thiery J, Seidel D. Safety and effectiveness of long term LDL-apheresis in patients at high risk. Curr Opin Lipidol (in press).
20. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous form of familial hypercholesterolemia. Lancet 1975;1:1208-11.